Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

C4 Therapeutics (CCCC) Debt Ratio (2020 - 2023)

C4 Therapeutics has reported Debt Ratio over the past 4 years, most recently at 0.03 for Q2 2023.

  • For Q2 2023, Debt Ratio rose 22.03% year-over-year to 0.03; the TTM value through Jun 2023 reached 0.03, up 22.03%, while the annual FY2022 figure was 0.03, 25.42% up from the prior year.
  • Debt Ratio for Q2 2023 was 0.03 at C4 Therapeutics, roughly flat from 0.03 in the prior quarter.
  • Over five years, Debt Ratio peaked at 0.04 in Q3 2020 and troughed at 0.02 in Q2 2021.
  • A 4-year average of 0.03 and a median of 0.02 in 2020 define the central range for Debt Ratio.
  • Biggest five-year swings in Debt Ratio: plummeted 51.64% in 2021 and later grew 29.73% in 2023.
  • Year by year, Debt Ratio stood at 0.03 in 2020, then fell by 15.42% to 0.02 in 2021, then increased by 25.42% to 0.03 in 2022, then increased by 3.41% to 0.03 in 2023.
  • Business Quant data shows Debt Ratio for CCCC at 0.03 in Q2 2023, 0.03 in Q1 2023, and 0.03 in Q4 2022.